Statin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial

Area of Science:

• Cardiovascular Pharmacology
• Neuropsychopharmacology
• Behavioral Science

Background:

• Cholesterol-lowering medications, statins, have been anecdotally linked to aggression, but their typical effects remain uncharacterized.
• Existing case studies suggest statins may increase aggression, yet they also possess mechanisms that could potentially reduce it.

Purpose of the Study:

• To characterize the usual effects of statins on aggression, differentiating between sexes and considering age and baseline aggression levels.
• To investigate the influence of testosterone changes, sleep disturbances, and age on statin-induced behavioral alterations.

Main Methods:

• A double-blind, sex-stratified randomized trial involving 1016 adults (men and postmenopausal women) assigned to placebo, simvastatin, or pravastatin for six months.
• Behavioral aggression was assessed using the Overt-Aggression-Scale-Modified-Aggression-Subscale (OASMa).
• Exploratory analyses examined the impact of baseline aggression, testosterone changes, sleep, and age.

Main Results:

• A significant sex-statin interaction was observed, with statins tending to decrease aggression in men (especially on pravastatin) and increase aggression in women.
• These effects were more pronounced in participants with low baseline aggression.
• In men, statins lowered testosterone and increased sleep problems, with testosterone drop predicting aggression decline and sleep worsening predicting aggression increase.
• In women, statins increased aggression, particularly in those of typical postmenopausal age and with low baseline aggression.

Conclusions:

• Statin-induced aggression effects are sex- and age-dependent, generally decreasing aggression in men and increasing it in women.
• Individuals with low baseline aggression exhibited more pronounced and readily evident statin effects on aggression, likely due to lower change variance.